In the present study we have, for the first time, examined whether HRGs can similarly promote erbB3/PI3K/AKT signalling and effectively circumvent the inhibitory effects of the anti-EGFR agent gefitinib on the growth and invasion of an EGFR-positive Tam-R breast cancer cell line [32]. This evidence concerns the gene EGFR and breast cancer.